Coeptis Therapeutics Holdings Inc COEP

NAS: COEP | ISIN: US19207A1088   17/05/2024
0,350 USD (-1,46%)
(-1,46%)   17/05/2024

8 mei 2024 · Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 · Persbericht

2 mei 2024 · Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting · Persbericht

2 april 2024 · Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award · Persbericht

26 februari 2024 · Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK · Persbericht

7 februari 2024 · Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections · Persbericht

4 januari 2024 · Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 · Persbericht

4 december 2023 · Coeptis Therapeutics to Present at the Emerging Growth Conference · Persbericht

31 oktober 2023 · Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 · Persbericht

24 oktober 2023 · Coeptis Therapeutics Announces $2 Million Private Placement · Persbericht

11 oktober 2023 · Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology · Persbericht

9 oktober 2023 · Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies · Persbericht

4 oktober 2023 · Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting · Persbericht

27 september 2023 · Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa · Persbericht

14 september 2023 · Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection · Persbericht

11 september 2023 · Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment · Persbericht

30 augustus 2023 · Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer · Persbericht

17 augustus 2023 · Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics · Persbericht

1 augustus 2023 · Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic · Persbericht

16 juni 2023 · Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering · Persbericht

14 juni 2023 · Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering · Persbericht

Mijn selecties